In second reversal, FDA gives uniQure a green light to seek accelerated approvalnews2026-06-17T15:40:18+00:00June 17th, 2026|Endpoints News|
Update: Spot Bio launches with $40M to study non-viral gene therapy for muscular dystrophynews2026-06-17T11:00:12+00:00June 17th, 2026|Endpoints News|
B cell therapy maker Be Bio stops hemophilia trialnews2026-06-16T19:05:16+00:00June 16th, 2026|Endpoints News|
SonoThera raises $125M for non-viral gene therapy approachnews2026-06-10T15:23:43+00:00June 10th, 2026|Endpoints News|
Grace Science says FDA bottleneck jeopardizes rare disease therapynews2026-06-09T18:22:35+00:00June 9th, 2026|Endpoints News|
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseasesnews2026-06-03T11:00:46+00:00June 3rd, 2026|Endpoints News|
FDA details flexibilities for new cell and gene therapies to leverage past datanews2026-06-02T17:40:48+00:00June 2nd, 2026|Endpoints News|
Legend Biotech shares first in vivo CAR-T data, its next act after Carvyktinews2026-06-02T13:31:07+00:00June 2nd, 2026|Endpoints News|
Epigenetic editing shows promise against chronic hep B infectionsnews2026-06-01T18:48:12+00:00June 1st, 2026|Endpoints News|
#ASCO26: After leaving Legend, Frank Fan is ready to showcase his next projectnews2026-05-28T14:47:43+00:00May 28th, 2026|Endpoints News|
